Will Evogene (USA Stocks:EVGN) continue to grow in December?
 | By Ellen Johnson | Macroaxis Story |
Evogene, a player in the biotechnology sector, has been navigating a challenging financial landscape. With its fiscal year wrapping up in December, the company faces the critical question of whether it can maintain its growth trajectory. Despite generating a total revenue of $5.6 million, Evogene reported a net income loss of $23.9 million, highlighting the financial hurdles it must overcome. The company's operating income also stands at a loss of $26.4 million, further emphasizing the need for strategic adjustments. As Evogene continues to innovate within its industry, investors are keenly watching to see if it can leverage its intangible assets, valued at $13.2 million, to turn the tide and sustain growth in the coming months. Evogene is set to release its earnings today, sparking interest among those who follow the biotechnology sector. It's worth taking a closer look at Evogene as a distinct option in this field. A key aspect to consider is the company's capacity to handle its long-term financial commitments. This includes making timely interest payments, settling the principal amount on its debts, and covering other fixed obligations like lease payments.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Michael Smolkin
Considering a leveraged investment in Evogene, it's crucial to note the company's substantial net income loss of 23.9M and a negative cash flow from operating activities of 21.6M. These figures suggest that while there might be potential for growth, the financial strain could pose significant risks for investors looking to leverage their positions.
Main Points
Evogene has $1.14 million in liabilities and a Debt to Equity (D/E) ratio of 0.05, indicating it might not be leveraging borrowing opportunities effectively. The asset utilization ratio, which shows how much revenue is generated per dollar of assets, stands at 11.04%. This means Evogene earns $0.11 for every dollar of assets. A rising asset utilization ratio suggests the company is becoming more efficient in using its assets for daily operations.Evogene financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Evogene, including all of Evogene's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Evogene assets, the company is considered highly leveraged. Understanding the composition and structure of overall Evogene debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.
Understanding Evogene Total Debt
Evogene liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Evogene has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Evogene balance sheet include debt obligations and money owed to different Evogene vendors, workers, and loan providers. Below is the chart of Evogene main long-term debt accounts currently reported on its balance sheet. You can use Evogene financial leverage analysis tool to get a better grip on understanding its financial positionHow important is Evogene's Liquidity
Evogene financial leverage refers to using borrowed capital as a funding source to finance Evogene ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Evogene financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Evogene's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Evogene's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Evogene's total debt and its cash.
What is driving Evogene Investor Appetite?
Evogene reported the previous year's revenue of 5.64 M. Net Loss for the year was (23.88 M) with profit before overhead, payroll, taxes, and interest of 766 K. In the stock market, past performance is not always indicative of future results. For Evogene (NASDAQ: EVGN), the challenge lies in maintaining its growth momentum as December approaches. With a net working capital of $27.5 million and a cash reserve of $20.8 million, the company has a solid financial cushion. However, the biotechnology firm faces a high probability of bankruptcy at 82.43%, which could pose significant risks to its growth trajectory. Investors should weigh these factors carefully, considering both the potential for innovation in the healthcare sector and the financial hurdles Evogene must overcome.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Evogene. Please refer to our Terms of Use for any information regarding our disclosure principles.